Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:


Researchers identified an important signaling molecule of cell communication


"Nature" publication gives hope to a more targeted effect of medicine

International scientists led by Carsten Hoffmann and Martin Lohse of the University Würzburg, Germany, identified for the first timeβ-Arrestin as an independent signaling molecule. The protein modulates a pharmaceutically important pathway. The results were published in the prestigious scientific journal "Nature". It leads to new drug targets, for example in pain therapy.

Schematic drawing of β(beta)Arrestin2. With these biosensors (colored), scientists were able to study spatial movements of the protein in real time in living cells.

Group Hoffmann, Rudolf Virchow Center

The most important target for drug research are G-protein coupled receptors (GPCR). Around 30 percent of all medicine work on more than 800 members of this class of proteins. GPCRs are crucial for cell communication and the processing of pain and sensory stimuli.

The protein β-Arrestin regulates GPCR. However, it remained unclear how it functions on a molecular level. With biosensors, scientists were able to explain the interaction on a temporal and spatial level. "When I discovered β-Arrestin in 1990, it looked like, it is there to disable receptors," said Lohse. "That it acts as an independent signaling molecule, we could demonstrate only now with the latest technology."

Experiments showed that β-Arrestin was transferred into an active state by receptors, which lasted longer that its interaction with the receptor. The change was so significant that a cycle of activation and deactivation of β-Arrestin was detectable - a criterion for the definition of an independent signaling molecule. At the same time, American collaborators were able to show that the type of activation of β-Arrestin depends on the activating receptor.

Their results will be also published in "Nature". The exchange with American colleagues pushed the project enormously. Hoffmann became aware of their work during a conference. "This project went through ups and downs," Hoffmann remembers. "We often had to be patient, but it was worth it."

By molecular reinforcing or blocking of β-Arrestin, the effect of future drugs could be more specific and associated with fewer side effects. Due to their diversity, GPCR and now possibly β-Arrestin are important targets for pharmaceutical substances. Hoffmann expects a particularly good progress in long-term treatment with strong painkillers.

The body gets used to the medicine and becomes increasingly depended on higher doses. At the same time, side effect will appear even stronger. New medicine targeting specifically β-Arrestin on a molecular level could minimize this tolerance and therefore its side effects, and could enable a more effective long-term therapy.

Hoffmann is optimistic about future projects. As a next step, he wants to test whether activation of β-Arrestin can be changed by model substances. "That would be the first step to new medical drugs."

Publication: Susanne Nuber, Ulrike Zabel, Kristina Lorenz, Andreas Nuber, Graeme Milligan, Andrew B. Tobin, Martin J. Lohse, Carsten Hoffmann β-Arrestin biosensors reveal a rapid, receptor-dependent activation/deactivation cycle. Nature doi:10.1038/nature17198

Prof Carsten Hoffmann joined the Rudolf Virchow Center for Experimental Biomedicine of the University of Würzburg in 2012.
Prof Martin Lohse is founder and chair of the Rudolf Virchow Center and future scientific manager and chairman of the Max Delbück Center for Molecular Medicine (MDC) in Berlin.

Research group Hoffmann:

Research group Lohse:

The Rudolf Virchow Center for Experimental Biomedicine is a central institution of the University of Würzburg. Research groups are working on target proteins, which are essential for cellular function and therefore central to health and disease.

Prof. Dr. Carsten Hoffmann
Tel. 0049 (0)931 3148304,

Prof. Dr. Martin Lohse
Tel. 0049 (0)931 3148400,

Dr. Daniela Diefenbacher (Press Office, Rudolf Virchow Center)
Tel. 0049 (0)931 3188631,

Weitere Informationen:

Dr. Daniela Diefenbacher | idw - Informationsdienst Wissenschaft

More articles from Life Sciences:

nachricht Gene therapy shows promise for treating Niemann-Pick disease type C1
27.10.2016 | NIH/National Human Genome Research Institute

nachricht 'Neighbor maps' reveal the genome's 3-D shape
27.10.2016 | International School of Advanced Studies (SISSA)

All articles from Life Sciences >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Etching Microstructures with Lasers

Ultrafast lasers have introduced new possibilities in engraving ultrafine structures, and scientists are now also investigating how to use them to etch microstructures into thin glass. There are possible applications in analytics (lab on a chip) and especially in electronics and the consumer sector, where great interest has been shown.

This new method was born of a surprising phenomenon: irradiating glass in a particular way with an ultrafast laser has the effect of making the glass up to a...

Im Focus: Light-driven atomic rotations excite magnetic waves

Terahertz excitation of selected crystal vibrations leads to an effective magnetic field that drives coherent spin motion

Controlling functional properties by light is one of the grand goals in modern condensed matter physics and materials science. A new study now demonstrates how...

Im Focus: New 3-D wiring technique brings scalable quantum computers closer to reality

Researchers from the Institute for Quantum Computing (IQC) at the University of Waterloo led the development of a new extensible wiring technique capable of controlling superconducting quantum bits, representing a significant step towards to the realization of a scalable quantum computer.

"The quantum socket is a wiring method that uses three-dimensional wires based on spring-loaded pins to address individual qubits," said Jeremy Béjanin, a PhD...

Im Focus: Scientists develop a semiconductor nanocomposite material that moves in response to light

In a paper in Scientific Reports, a research team at Worcester Polytechnic Institute describes a novel light-activated phenomenon that could become the basis for applications as diverse as microscopic robotic grippers and more efficient solar cells.

A research team at Worcester Polytechnic Institute (WPI) has developed a revolutionary, light-activated semiconductor nanocomposite material that can be used...

Im Focus: Diamonds aren't forever: Sandia, Harvard team create first quantum computer bridge

By forcefully embedding two silicon atoms in a diamond matrix, Sandia researchers have demonstrated for the first time on a single chip all the components needed to create a quantum bridge to link quantum computers together.

"People have already built small quantum computers," says Sandia researcher Ryan Camacho. "Maybe the first useful one won't be a single giant quantum computer...

All Focus news of the innovation-report >>>



Event News

#IC2S2: When Social Science meets Computer Science - GESIS will host the IC2S2 conference 2017

14.10.2016 | Event News

Agricultural Trade Developments and Potentials in Central Asia and the South Caucasus

14.10.2016 | Event News

World Health Summit – Day Three: A Call to Action

12.10.2016 | Event News

Latest News

How nanoscience will improve our health and lives in the coming years

27.10.2016 | Materials Sciences

OU-led team discovers rare, newborn tri-star system using ALMA

27.10.2016 | Physics and Astronomy

'Neighbor maps' reveal the genome's 3-D shape

27.10.2016 | Life Sciences

More VideoLinks >>>